Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open Label, Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer

Next Previous
X
Search
Trial Profile

A Randomized, Open Label, Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pamrevlumab (Primary) ; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic ductal carcinoma
  • Focus Adverse reactions
  • Sponsors FibroGen

    • Most Recent Events

    • 05 Feb 2024 According to a FibroGen media release, company announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM ET to include information on the mechanism of action of pamrevlumab in Phase 1/2 trial, Precision Promise Phase 2/3 trial and LAPIS Phase 3 trial.
    • 27 Apr 2022 Status changed from active, no longer recruiting to completed.
    • 27 Jan 2021 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top